SYMBIOTEC
1 call
Concalls & earnings callsSymbiotec Pharmalab Limited
Every summarised call, newest first. Latest is Q1 FY27, held 22 Sept 2026.
Latest quarter
Q1 FY27 snapshot
Open full brief →Q1 FY27 was driven by the established steroid API business while consolidated profit was reduced by operating costs and depreciation from the new biotech CDMO and complex injectables facilities awaiting first revenues in the next 6 to 12 months.
| Metric | This quarter | Change | Five-quarter trend |
|---|---|---|---|
| Consolidated revenue Q1 FY27 | ₹218 Cr | growth of 7% YoY | |
| API revenue Q1 FY27 | ₹215 Cr | growth of 6% YoY | |
| API EBITDA Q1 FY27 | ₹66 Cr | +9% YoY growth | |
| Consolidated EBITDA Q1 FY27 | ₹45 Cr | — |
Latest guidance
- Targeting 20% and 25% growth for this current fiscal year in revenues and EBITDA respectively, plus-minus 5% due to global operating environmental uncertainties
- New business revenues expected to commence in the next 6 to 12 months
- H2 expected to be very strong on milestone cash flows with some small revenues from biotech CDMO services in quarter four
- Continue to invest INR200 crores to INR250 crores each year for the next two to three years funded by internal accruals and partners' capital
- API gross margins expected around 60% and EBITDA margins close to 30%
- R&D investment of 3% to 4% of sales expected to continue, probably with a slight increase to about 5% in the future
Said on the Q1 FY27 call.
Call history
- Q1 FY27Positive tone
Q1 FY27 was driven by the established steroid API business while consolidated profit was reduced by operating costs and depreciation from the new biotech CDMO and complex injectables facilities awaiting first revenues in the next 6 to 12 months.
- Consolidated revenue Q1 FY27
- ₹218 Crgrowth of 7% YoY
- API revenue Q1 FY27
- ₹215 Crgrowth of 6% YoY